About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker PTCT · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 6, 2026Study of PTC844 in Participants With Active Rheumatoid Arthritis
NCT07779616 · Rheumatoid Arthritis
PTC844, Placebo
PTCT
PTC Therapeutics
Phase 2Recruiting
was not yet recruiting
75Sep 30, 2027Registry ↗
Oct 23, 2026A Study of Sepiapterin in Participants With Phenylketonuria (PKU)
NCT06302348 · Phenylketonuria
Sepiapterin
PTCT
PTC Therapeutics
Phase 3Recruiting56Feb 28, 2031Registry ↗
Oct 8, 2026Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBM…
NCT01247207 · Duchenne Muscular Dystrophy
Ataluren
PTCT
PTC Therapeutics
Phase 3Terminated265Feb 10, 2026Registry ↗
Sep 9, 2026A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria
NCT05166161 · Phenylketonuria
PTC923
PTCT
PTC Therapeutics
Phase 3Completed247Jul 21, 2026Registry ↗
Aug 14, 2026Long-Term Efficacy Study of Vatiquinone for the Treatment of Friedreich's Ataxia (FA)
NCT07681713 · Friedreich's Ataxia
Vatiquinone
PTCT
PTC Therapeutics
Phase 3Not yet recruiting120Mar 15, 2029Registry ↗
Apr 24, 2026A Study of SmartFlow Magnetic Resonance (MR) Compatible Ventricular Cannula for Administering Elado…
NCT04903288 · AADC Deficiency
Eladocagene Exuparvovec
PTCT
PTC Therapeutics
Phase 2Active, not recruiting13May 22, 2023Registry ↗
Apr 13, 2026A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Fri…
NCT04577352 · Friedreich Ataxia
Vatiquinone, Placebo
PTCT
PTC Therapeutics
Phase 2/3Completed146Apr 4, 2023Registry ↗
Mar 31, 2026A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Partic…
NCT04378075 · Mitochondrial Diseases, Drug Resistant Epilepsy
Vatiquinone, Placebo
PTCT
PTC Therapeutics
Phase 2/3Terminated68Mar 18, 2023Registry ↗
Mar 10, 2026Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy
NCT03179631 · Muscular Dystrophy, Duchenne, Muscular Dystrophies
Ataluren, PLACEBO
PTCT
PTC Therapeutics
Phase 3Completed360Mar 5, 2022Registry ↗
Feb 24, 2026Registry of Translarna (Ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)
NCT02369731 · Muscular Dystrophy, Duchenne
PTCT
PTC Therapeutics
—Completed316Mar 31, 2025Registry ↗
Dec 22, 2025A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondria…
NCT05218655 · Inherited Mitochondrial Disease
Vatiquinone
PTCT
PTC Therapeutics
Phase 3Completed101Apr 15, 2025Registry ↗
Oct 30, 2025A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia
NCT05515536 · Friedreich Ataxia
Vatiquinone
PTCT
PTC Therapeutics
Phase 3Active, not recruiting130Dec 31, 2027Registry ↗
Aug 22, 2025A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia
NCT05485987 · Friedreich Ataxia
Vatiquinone
PTCT
PTC Therapeutics
Phase 2Completed5Aug 29, 2024Registry ↗
Aug 1, 2025Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis…
NCT05349721 · Amyotrophic Lateral Sclerosis
PTC857, Placebo
PTCT
PTC Therapeutics
Phase 2Terminated336Sep 26, 2024Registry ↗
Jun 13, 2025A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)
NCT05269355 · Leiomyosarcoma
Unesbulin, Dacarbazine
PTCT
PTC Therapeutics
Phase 2/3Terminated359Jun 17, 2024Registry ↗
Oct 23, 2024Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome
NCT02352896 · Leigh Syndrome
EPI-743
PTCT
PTC Therapeutics
Phase 2Completed30Oct 30, 2023Registry ↗
Apr 1, 2024A Study to Evaluate the Safety and Pharmacokinetics of Ataluren in Participants From ≥6 Months to <…
NCT04336826 · Nonsene Mutation Duchenne Muscular Dystrophy
Ataluren
PTCT
PTC Therapeutics
Phase 2Completed6Aug 7, 2023Registry ↗
Mar 15, 2024A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyo…
NCT03761095 · Leiomyosarcoma
Unesbulin, Dacarbazine
PTCT
PTC Therapeutics
Phase 1Completed41Feb 5, 2024Registry ↗
Jan 23, 2024EPI-743 for Mitochondrial Respiratory Chain Diseases
NCT01370447 · Mitochondrial Diseases
EPI-743
PTCT
PTC Therapeutics
—No longer available——Registry ↗
Jan 10, 2024A Study of PTC923 in Participants With Phenylketonuria
NCT05099640 · Phenylketonuria
PTC923, Placebo
PTCT
PTC Therapeutics
Phase 3Completed157Apr 3, 2023Registry ↗
Nov 14, 2023A Study of PTC923 (CNSA-001) in Primary Tetrahydrobiopterin (BH4) Deficient Participants With Hyper…
NCT03519711 · BH4 Deficiency, Hyperphenylalaninemia
PTC923
PTCT
PTC Therapeutics
Phase 1/2Completed8Oct 2, 2020Registry ↗
Jun 26, 2023A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With C…
NCT04439071 · Pneumonia, COVID-19
PTC299, SOC
PTCT
PTC Therapeutics
Phase 2/3Terminated189Jul 20, 2022Registry ↗
Jun 27, 2022A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)
NCT03783923 · Limb-Girdle Muscular Dystrophy
Deflazacort
PTCT
PTC Therapeutics
Phase 3Terminated11Jan 1, 2021Registry ↗
May 27, 2022Study of Ataluren in Participants With Nonsense Mutation Aniridia
NCT02647359 · Aniridia
Ataluren, Placebo
PTCT
PTC Therapeutics
Phase 2Completed39Jan 22, 2021Registry ↗
Apr 5, 2022A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystro…
NCT03796637 · Duchenne Muscular Dystrophy
Ataluren
PTCT
PTC Therapeutics
Phase 2Completed6Jun 3, 2019Registry ↗
Apr 5, 2022A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystro…
NCT03648827 · Duchenne Muscular Dystrophy
Ataluren
PTCT
PTC Therapeutics
Phase 2Completed20Oct 23, 2020Registry ↗
Feb 2, 2022Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias
NCT03761069 · Leukemia, Myeloid, Acute, AML
PTC299
PTCT
PTC Therapeutics
Phase 1Terminated33Dec 28, 2021Registry ↗
Jan 5, 2022A Study of CNSA-001 in Women With Diabetic Gastroparesis
NCT03712124 · Gastroparesis
CNSA-001, Placebo
PTCT
PTC Therapeutics
Phase 2Completed21Sep 8, 2019Registry ↗
Nov 25, 2020Study of Ataluren for Previously Treated Participants With Nonsense Mutation Duchenne/Becker Muscul…
NCT01557400 · Duchenne Muscular Dystrophy, Becker Muscular Dystrophy
Ataluren
PTCT
PTC Therapeutics
Phase 3Completed94Jan 19, 2018Registry ↗
Oct 29, 2020Phase 2a Extension Study of Ataluren (PTC124) in Duchenne Muscular Dystrophy (DMD)
NCT00759876 · Duchenne Muscular Dystrophy
Ataluren
PTCT
PTC Therapeutics
Phase 2Terminated36May 17, 2010Registry ↗
Oct 19, 2020Extension Study of Ataluren (PTC124) in Cystic Fibrosis
NCT01140451 · Cystic Fibrosis
Ataluren
PTCT
PTC Therapeutics
Phase 3Completed191Dec 2, 2013Registry ↗
Oct 14, 2020Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS)
NCT02460679 · Amyotrophic Lateral Sclerosis
EPI-589
PTCT
PTC Therapeutics
Phase 2Completed19Feb 23, 2018Registry ↗
Aug 31, 2020Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia
NCT01728064 · Friedreich's Ataxia
Placebo, EPI-743 400 mg
PTCT
PTC Therapeutics
Phase 2Completed60Oct 31, 2015Registry ↗
Aug 31, 2020Safety and Efficacy Study of EPI-743 in Children With Leigh Syndrome
NCT01721733 · Leigh Syndrome
Placebo, EPI-743 15 mg/kg
PTCT
PTC Therapeutics
Phase 2Completed35Feb 28, 2015Registry ↗
Aug 28, 2020Study of Ataluren in ≥2 to <5 Year-Old Male Participants With Duchenne Muscular Dystrophy
NCT02819557 · Duchenne Muscular Dystrophy
Ataluren
PTCT
PTC Therapeutics
Phase 2Completed14Feb 9, 2018Registry ↗
Aug 11, 2020An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy
NCT02090959 · Muscular Dystrophy, Duchenne, Muscular Dystrophies
Ataluren
PTCT
PTC Therapeutics
Phase 3Terminated219Jun 12, 2018Registry ↗
Aug 4, 2020Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)
NCT01826487 · Muscular Dystrophy, Duchenne, Muscular Dystrophies
Ataluren, Placebo
PTCT
PTC Therapeutics
Phase 3Completed230Aug 20, 2015Registry ↗
Jul 29, 2020Study of Ataluren (PTC124) in Nonambulatory Participants With Nonsense-Mutation-Mediated Duchenne/B…
NCT01009294 · Duchenne Muscular Dystrophy, Becker Muscular Dystrophy
Ataluren, Chronic Corticosteroid Therapy
PTCT
PTC Therapeutics
Phase 2Terminated6Mar 23, 2010Registry ↗
Jul 15, 2020Phase 2B Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)
NCT00847379 · Duchenne Muscular Dystrophy, Becker Muscular Dystrophy
Ataluren
PTCT
PTC Therapeutics
Phase 2Terminated173May 24, 2010Registry ↗
Jul 7, 2020Ataluren for Nonsense Mutation Methylmalonic Acidemia
NCT01141075 · Amino Acid Metabolism, Inborn Errors
Ataluren
PTCT
PTC Therapeutics
Phase 2Terminated11Nov 3, 2011Registry ↗
Jun 16, 2020Study of Ataluren (PTC124) in Hemophilia A and B
NCT00947193 · Hemophilia A, Hemophilia B
Ataluren
PTCT
PTC Therapeutics
Phase 2Terminated13Aug 30, 2011Registry ↗
Jun 11, 2020Safety and Efficacy of Ataluren (PTC124) for Cystic Fibrosis
NCT00237380 · Cystic Fibrosis
Ataluren
PTCT
PTC Therapeutics
Phase 2Completed24May 31, 2006Registry ↗
May 14, 2020Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF)
NCT02139306 · Cystic Fibrosis
Ataluren (PTC124®), Placebo
PTCT
PTC Therapeutics
Phase 3Completed279Nov 2016Registry ↗
May 14, 2020Study of Ataluren (PTC124™) in Cystic Fibrosis
NCT00803205 · Cystic Fibrosis
Ataluren, Placebo
PTCT
PTC Therapeutics
Phase 3Completed238Nov 12, 2011Registry ↗
Apr 27, 2020Extension Study of Ataluren in Participants With Nonsense Mutation Cystic Fibrosis
NCT02456103 · Cystic Fibrosis
Ataluren
PTCT
PTC Therapeutics
Phase 3Terminated246Jun 2, 2017Registry ↗
Apr 7, 2020Phase 2B Study of PTC124 (Ataluren) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)
NCT00592553 · Duchenne Muscular Dystrophy, Becker Muscular Dystrophy
Ataluren, Placebo
PTCT
PTC Therapeutics
Phase 2Completed174Dec 31, 2009Registry ↗
Mar 25, 2020Study of Ataluren (PTC124) in Cystic Fibrosis
NCT02107859 · Cystic Fibrosis
Ataluren
PTCT
PTC Therapeutics
Phase 3Terminated61Jun 5, 2017Registry ↗
Mar 6, 2020A Study of Ataluren in Pediatric Participants With Cystic Fibrosis
NCT00458341 · Cystic Fibrosis
Ataluren
PTCT
PTC Therapeutics
Phase 2Completed30Feb 29, 2008Registry ↗
Oct 7, 2019A Phase 2 Open Label Extension Study in Participants With Nonsense Mutation Aniridia
NCT04117880 · Aniridia
Ataluren
PTCT
PTC Therapeutics
Phase 2Withdrawn0Jan 31, 2021Registry ↗
Jun 21, 2019A Study of Deflazacort (Emflaza®) in Participants With Duchenne Muscular Dystrophy (DMD)
NCT03642145 · Duchenne Muscular Dystrophy
Deflazacort
PTCT
PTC Therapeutics
Phase 3Withdrawn0Jul 31, 2021Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:51 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances